8:00 am Morning Coffee & Networking


Welcome to the 4th RAS Targeted Drug Development Summit! For the first time since 2019, this community will be united once again in Boston. Grab a coffee, reconnect with peers, & settle in for a jam-packed conference ahead of the keynote opening sessions

Keynote Plenary Session: Updates from RAS Global Leaders

9:20 am Chair’s Opening Remarks

9:30 am Keynote Opening Address: A Historic Review to Celebrating 40 Years of Research Against RAS-Mutant Cancers

  • Channing Der Professor, University of North Carolina - Chapel Hill


  • After forty years since the isolation identification of the first human onco cancer gene, we revisit and review a history of the directions taken to target RAS
  • From multitude thousands of fantastic efforts strategies taken to targeting RAS, we can consider assess a state-of-the-art in RAS therapeutics
  • At the milestone of the first-ever targeted RAS therapeutics, we deliberate future issues and opportunities for this industry

10:00 am Biomarker Insights from KRAS P.G12C-Mutated Subjects Treated with Sotorasib in Codebreak 100


  • Baseline biomarker subgroup associations with response in NSCLC subjects
  • 2-year follow-up assessing biomarker correlates for NSCLC subjects deriving long-term benefit from sotorasib treatment
  • Analysis of acquired mutations NSCLC and CRC to treatment to inform rational combo therapy

10:30 am Targeting Tumors with KRAS G12C Mutations with Adagrasib (MRTX849): Current Status & Future Questions

  • Joshua Mason Director, Medical Affairs Strategy, Mirati Therapeutics


  • History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C
  • Clinical progress of KRAS G12C inhibitors (eg, adagrasib) in the clinic
  • Future questions and directions for targeting KRAS G12C

11:00 am Development of KRAS Inhibitors – Updated from Boehringer Ingelheim

  • Marco Hofmann Director & Group Leader - Scientific, Boehringer Ingelheim

11:30 am Morning Break & Speed Networking

Track A: Accelerating Discovery & Emerging Strategies

High-Value Modalities Beyond Small Molecule Approaches to Target RAS Driven Cancers

12:30 pm Lymph-Node Targeted Peptide Vaccination Promotes mKRAS-Specific T Cell Immunity & Enhances TCR-T Cell Therapy Against Solid Tumors

  • Peter DeMuth Chief Scientific Officer, Elicio Therapeutics


  • The AMP platform enables enhanced lymph node delivery of peptide immunogens and molecular adjuvants to potently stimulate T cell immunity
  • AMP-vaccination promotes expansion and functional enhancement of endogenous and adoptively transferred mKRAS-specific T cells in vitro and in vivo
  • AMP-vaccine combination with TCR-T cell therapy promotes anti-tumor efficacy in vivo

1:00 pm Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay

  • Hicham Zegzouti Senior Research Scientist - Group Leader -, Promega Corporation


  • Analyze RAS pathway activation and inhibition through the detection of phosphorylated ERK with a new bioluminescent immunoassay technology, which streamlines workflow and is adaptable to high throughput screening.
  • Rank order potencies of allele specific inhibitors within cell lines harboring various activating KRAS mutations such as G12C, G12D and G12V.
  • Determine potency of drug candidates across modalities, including PROTAC targeting selective degradation of KRAS G12C.

1:30 pm Extrahepatic Nucleotide Delivery with Self-Assembling Peptide-Based Nanostructures for RNAi against KRAS


Self-assembling peptide-nucleotide (siRNA, mRNA) polyplexes avoid sequestration in liver, track to myriad pathologies, but do not distribute to tissues/organs with normal vascular barriers

Following cell uptake, the peptide moiety itself facilitates rapid and complete endosomal escape and KRAS siRNA release into cytoplasm to inhibit KRAS production

Peptide-nucleotide polyplexes are safe and stable in circulation, cleared by the kidney, and are not immunogenic after serial dosing

Track B: Optimizing Translation & Pre-Clinical Development

Pre-Clinical Insights into Novel Checkpoint Inhibitors & Combination Approaches

12:30 pm WT RAS Signalling is an Essential Therapeutic Target In RAS-Mutated Cancers

  • Robert Kortum Assistant Professor, Uniformed Services University of the Health Sciences - USUHS


  • RAS isoforms differentially activate RAF/MEK/ERK and PI3K/AKT effector pathways
  • Non-mutated (wild type) RAS family members activate RAS effectors that are activated poorly by mutated RAS
  • Combined inhibition of mutated RAS and WT RAS signalling synergistically kills RAS-mutated cancers

1:00 pm Application of a quantitative systems pharmacology model to support differentiation of ASP2453, a novel KRASG12C inhibitor


  • KRASG12C mutations lead to constitutive proliferation signaling and are prevalent across human cancers. Sotorasib, a KRASG12C inhibitor, was recently approved for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, and several other KRASG12C inhibitors are in clinical trials. 
  • ASP2453 is a novel, highly-potent, and selective inhibitor of KRASG12C. Will ASP2453 show a more favorable clinical response compared to its competitors? 
  • To address this question, we developed a quantitative systems pharmacology (QSP) model linking KRAS signaling to tumor growth. Virtual clinical trial simulations using the QSP model suggest ASP2453 will exhibit superior antitumor efficacy in patients, supporting potential differentiation and critical thinking for clinical trials.

1:30 pm Targeting KRAS: Pre-Clinical Validation & Therapeutic Perspectives to Overcome Drug Resistance

  • Chiara Ambrogio Associate Professor of, Molecular Biology, University of Torino


  • New biomarker needed to predict sensitivity to direct KRAS inhibitors
  • Acquired versus adaptive mechanisms of resistance to G12C inhibitors
  • Novel therapeutic strategies to overcome resistance

Track C: Advancing Clinical Trials & Development

Clinical Insights from RAS Targeted Therapies Leveraging the Immune System

12:30 pm Novel Cell Therapy Method to Generate Antigen Presenting Cells for Multiple KRAS Mutations

  • Scott Loughhead Sr. Director of Immuno-Oncology Research, SQZ Biotechnologies


  • SQZ APC mechanism overcomes challenges of previous cancer vaccines with CD8 T-cell activation and can be enhanced with mRNA cargo combinations
  • SQZ APC clinical program overview: Safety and manufacturability of SQZ’s APC candidate in solid tumors
  • Preclinical data for SQZ’s enhanced APC platform in targeting KRAS G12D and G12V mutation

1:00 pm Applying Real-World Data & Biological Tumor Modeling to KRAS-Related Drug Development

  • Julie Gerardi Vice President, Business Development, Life Sciences, Tempus, Inc. (Life Science)


  • Learn how Tempus uses real-world data and three-dimensional tumor modeling to advance discovery and translational research for KRAS-related drug development

1:30 pm Development of a Selective, Affinity-Enhanced T-Cell Receptor Bispecific Targeting KRASG12D Neoantigen Driven Cancers

  • Andrew Whale Associate Director, Pipeline Biology, Immunocore Ltd


  • CD3xTCR bispecific proteins (bsp) redirect polyclonal T cells to target intracellular proteins in cancer; TCR bsp offer an attractive opportunity to target KRAS G12D neoantigen peptides presented by cell surface human leukocyte antigen
  • We successfully engineered an off the shelf, soluble CD3xTCR bispecific molecule, IMC-KRAS G12D, that recognises a common shared KRAS G12D neoantigen peptide presented in the context of HLA A*11:01. IMC-KRAS G12D incorporates a TCR engineered with strong affinity, increased by over one million fold yet with remarkable ability to distinguish between KRAS G12D and KRAS WT

2:00 pm Lunch Break & Networking

3:00 pm Roundtable Session – Successes in Modalities Beyond Small Molecules

  • Imran Khan Senior Scientist, Bristol Myers Squibb
  • Meizhong Jin Senior Director, Oncology Chemistry , AstraZeneca


As this community continues progress targeting RAS mutants harnessing novel modalities, this session will lead the discussion into existing literature, data and ongoing challenges with RAS-mutant drugs leveraging novel degradation strategies, immune therapies and molecular glue approaches

3:00 pm Roundtable with KRASKickers: Bridging the RAS Gap Between Research & Survivors

  • Terri Conneran KRAS Cancer Survivor, Founding Director, KRAS Kickers


Whilst every day, more and more patients with RAS-mutant cancers are being diagnosed, it is critical that we understand the patient journey, and how critical patient perspectives are critical for guiding research. This session will lead discussion into making sense of RAS-mutant cancer biomarkers & the patient diagnostic journey

3:00 pm Roundtable Session – What Have We Learnt from AACR?

  • Channing Der Professor, University of North Carolina - Chapel Hill
  • Colin Weekes Associate Director - Pancreatic Cancer Research for MGHCC & Professor - Medicine, Harvard Medical School  


Following an array of data updates from RAS-mutant therapies at AACR, it is important that we take time to

reflect, digest and consider how this information can be used to guide our next steps. Leading professors will navigate us through what we know, and lead the conversation as we consider the future of RAS targeted therapies

3:30 pm Afternoon Break & Poster Session


Aiming to stimulate discussion in the oncology community about ongoing work and to promote collaboration between peers, we bring to you the RAS Poster Session, back for the third year. As the viability of targeting RAS as an effective therapeutic application against RAS driven cancers is closer than ever to approval, it is more important than ever to collaborate and learn with your peers as we continue to advance RAS targeted therapies through discovery and development. Join our dedicated session to share your latest data and have a first-look at what your peers are working on!

Tumor & Mutant Heterogeneity – Expanding Drugs Targeting Mutations Beyond G12C

4:30 pm NS1 Monobody Targeting the α4-α5 Allosteric Interface of RAS Inhibits Tumorigenesis In Vivo

  • Imran Khan Senior Scientist, Bristol Myers Squibb


  • NS1 Monobody binds to dimer interface of RAS
  • NS1 blocks RAS self-association that in turn impairs BRAF/CRAF heterodimerization
  • The intrinsic cell inhibition of mutant KRAS changes the phenotype of otherwise immunologically cold PDAC tumors by increasing infiltration of T cells

5:00 pm Disruption of the RAS-RAF1 Interaction: A New Synthetic Lethality Strategy for Selectively Blocking RAS-Driven Proliferation of Cancer Cells


  • Using our PPI-disruption identifying platform, ToRPPIDO, we have discovered several new compounds that allosterically disrupt the Ras-Raf1 protein-protein interaction by binding Raf1 in a new pocket distal to its Ras Binding Domain
  • STX200, a cell-permeable member of this set, exhibits a potent anti-proliferative activity against a variety of mutant RAS cancer lines
  • The anti-proliferative activity of STX200 is independent of the kinase activity of Raf1 in canonical MAPK signaling

5:30 pm Chemical Strategies for the Mutant-Specific Targeting of RAS-Driven Cancer

  • Ziyang Zhang Assistant Professor, University of California, Berkeley


  • New covalent chemistry enables mutant specific targeting of Ras mutants beyond G12C
  • The switch II pocket can be access in both GDP- and GTP-bound states
  • Chemo-immunological approach overcomes resistance to small molecule KRAS G12C inhibitors 

Enhancing Tissue Specificity & Understanding PK/PD Relationships in Pre-Clinical Settings

4:30 pm How Climb is Improving in vivo Workflows at Charles River


  • CD3xTCR bispecific proteins (bsp) redirect polyclonal T cells to target intracellular proteins in cancer; TCR bsp offer an attractive opportunity to target KRAS G12D neoantigen peptides presented by cell surface human leukocyte antigen
  • 45% reduction in study design time and improved design comprehensiveness
  • 66% improvement in study task visibility for technicians when capturing/confirming data collection
  • Projected 90% reduction in paper use at the technician level

4:45 pm Tumor/Biomarker-Specific Combination Strategies with the RAF/MEK Clamp VS-6766


  • VS-6766 blocks the RAS pathway through a novel RAF/MEK clamp mechanism
  • Rationale for ongoing combination trials with VS-6766 with defactinib or everolimus
  • Novel VS-6766 combinations for tumor/biomarkerspecific patient populations

Evaluating Clinical Data for Targeted Combination Therapies Harnessing Upstream & Downstream Molecules

4:30 pm Mapping the KRAS Resistome

  • Nick Goldner Chief Executive, Officer, & Co-Founder, ResistanceBio

4:45 pm Targeting RAS Mutations & MAPK Pathway Aberrations via Vertical Combination

  • Lusong Luo Senior Vice President, External Innovation, BeiGene


  • Vertical combination represents a useful approach to target the MAPK pathway aberrations including RAS mutations
  • The synergistic activity from inhibition of the different nodes of the MAPK pathway leads to more complete and sustained pathway inhibition
  • Inhibition of multiple nodes of the pathway suppresses the feedback activation of upstream signalling and potentially delay the development of drug resistances
  • Preclinical and clinical data of several vertical combinations support using this strategy to target MAPK pathway aberrations including RAS mutations

5:15 pm Clinical Development of RAF/MEK clamp VS-6766; Breakthrough Designation & Beyond


  • RAF/MEK clamp VS-6766 and FAK inhibitor defactinib are in clinical development in RAS/MAPK driven cancers
  • Clinical experience and progress in recurrent low-grade serous ovarian cancer (LGSOC) and KRAS mutant NSCLC will be presented
  • Future directions will be discussed – including clinical trials in new indications and combination treatment approaches

6:00 pm End of Conference Day One